Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 640

1.

Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease.

Welsh RC, Peterson ED, De Caterina R, Bode C, Gersh B, Eikelboom JW.

Am Heart J. 2019 Oct 23;218:100-109. doi: 10.1016/j.ahj.2019.09.006. [Epub ahead of print] Review.

PMID:
31715433
2.

PrevenTion of contrast-inducEd nephropAThy with urinE alkalinization: the TEATE study design.

Lombardi M, Molisana M, Genovesi E, De Innocentiis C, Limbruno U, Misuraca L, Moretti L, Di Vito L, Di Nicola M, Zimarino M, Renda G, De Caterina R.

J Cardiovasc Med (Hagerstown). 2019 Nov 4. doi: 10.2459/JCM.0000000000000892. [Epub ahead of print]

PMID:
31688431
3.

Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina.

Caselli C, Del Turco S, Ragusa R, Lorenzoni V, De Graaf M, Basta G, Scholte A, De Caterina R, Neglia D.

Cardiovasc Diabetol. 2019 Oct 31;18(1):144. doi: 10.1186/s12933-019-0949-3.

4.

The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design.

De Caterina R, Agnelli G, Laeis P, Unverdorben M, Rauer H, Wang CC, Nakamura M, Chiu KM, Reimitz PE, Koretsune Y, Chen C, Thee U, Kaburagi J, Kim YH, Choi WI, Yamashita T, Cohen A, Kirchhof P.

Clin Cardiol. 2019 Oct 25. doi: 10.1002/clc.23279. [Epub ahead of print]

5.

Hydroxytyrosol Modulates Adipocyte Gene and miRNA Expression Under Inflammatory Condition.

Scoditti E, Carpi S, Massaro M, Pellegrino M, Polini B, Carluccio MA, Wabitsch M, Verri T, Nieri P, De Caterina R.

Nutrients. 2019 Oct 17;11(10). pii: E2493. doi: 10.3390/nu11102493.

6.

Addenda online<br> Ferro e cardiopatia ischemica stabile - lezioni dallo scompenso cardiaco.

Corradi F, Fischetti I, De Caterina R.

G Ital Cardiol (Rome). 2019 Oct;20(10):0. doi: 10.1714/3228.32062. Italian. No abstract available.

PMID:
31593160
7.

[Iron and stable ischemic heart disease - lessons from heart failure].

Corradi F, Fischetti I, De Caterina R.

G Ital Cardiol (Rome). 2019 Oct;20(10):559-573. doi: 10.1714/3228.32055. Italian.

PMID:
31593159
8.

Prognostic Role of Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Low-to-Intermediate Sudden Cardiac Death Risk Score.

Todiere G, Nugara C, Gentile G, Negri F, Bianco F, Falletta C, Novo G, Di Bella G, De Caterina R, Zachara E, Re F, Clemenza F, Sinagra G, Emdin M, Aquaro GD.

Am J Cardiol. 2019 Oct 15;124(8):1286-1292. doi: 10.1016/j.amjcard.2019.07.023. Epub 2019 Jul 29.

PMID:
31447011
9.

Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis.

Merino JL, Lip GYH, Heidbuchel H, Cohen AA, De Caterina R, de Groot JR, Ezekowitz MD, Le Heuzey JY, Themistoclakis S, Jin J, Melino M, Winters SM, Merkely B, Goette A.

Europace. 2019 Nov 1;21(11):1633-1638. doi: 10.1093/europace/euz213.

10.

Platelet Indices and Risk of Death and Cardiovascular Events: Results from a Large Population-Based Cohort Study.

Patti G, Di Martino G, Ricci F, Renda G, Gallina S, Hamrefors V, Melander O, Sutton R, Engström G, De Caterina R, Fedorowski A.

Thromb Haemost. 2019 Nov;119(11):1773-1784. doi: 10.1055/s-0039-1694969. Epub 2019 Aug 20.

PMID:
31430798
11.

Why include the humanities in medical studies?

De Caterina R.

Intern Emerg Med. 2019 Aug 10. doi: 10.1007/s11739-019-02171-8. [Epub ahead of print] No abstract available.

PMID:
31401759
12.

Impaired adenylate cyclase signaling in acute myocardial ischemia: Impact on effectiveness of P2Y12 receptor antagonists.

Imam H, Nguyen TH, De Caterina R, Nooney VB, Chong CR, Horowitz JD, Chirkov YY.

Thromb Res. 2019 Sep;181:92-98. doi: 10.1016/j.thromres.2019.07.016. Epub 2019 Jul 23.

PMID:
31376607
13.

Cholesterol Lowering and Stroke: No Longer Room for Pleiotropic Effects of Statins - Confirmation from PCSK9 Inhibitor Studies.

Salvatore T, Morganti R, Marchioli R, De Caterina R.

Am J Med. 2019 Jul 11. pii: S0002-9343(19)30564-9. doi: 10.1016/j.amjmed.2019.06.029. [Epub ahead of print]

PMID:
31301293
14.

Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).

De Caterina R, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sá E, Weiss TW, Waltenberger J, Steffel J, de Groot JR, Levy P, Bakhai A, Zierhut W, Laeis P, Kerschnitzki M, Reimitz PE, Kirchhof P; ETNA-AF-Europe investigators.

BMC Cardiovasc Disord. 2019 Jul 12;19(1):165. doi: 10.1186/s12872-019-1144-x.

15.

[Atrial and left atrial appendage thrombosis in patients with atrial fibrillation: from pathophysiology to treatment].

Calabrò P, Gragnano F, Cesaro A, Pariggiano I, Patti G, Cavallari I, Parato VM, Renda G, De Caterina R; a nome del Gruppo di Studio sulla Trombosi della Società Italiana di Cardiologia.

G Ital Cardiol (Rome). 2019 Jun;20(6):374-383. doi: 10.1714/3165.31471. Italian.

PMID:
31184324
16.

Intraventricular flow patterns during right ventricular apical pacing.

Bianco F, Cicchitti V, Bucciarelli V, Chandra A, Di Girolamo E, Pedrizzetti G, Tonti G, Romano S, De Caterina R, Gallina S.

Open Heart. 2019 May 8;6(1):e001057. doi: 10.1136/openhrt-2019-001057. eCollection 2019.

17.

Proteomic analysis of the secretome of adipose tissue-derived murine mesenchymal cells overexpressing telomerase and myocardin.

Madonna R, Angelucci S, Di Giuseppe F, Doria V, Giricz Z, Görbe A, Ferdinandy P, De Caterina R.

J Mol Cell Cardiol. 2019 Jun;131:171-186. doi: 10.1016/j.yjmcc.2019.04.019. Epub 2019 May 2.

PMID:
31055035
18.

Aspirin for primary cardiovascular prevention: is there a need for risk stratification?

Aimo A, De Caterina R.

Eur Heart J. 2019 Sep 7;40(34):2922-2923. doi: 10.1093/eurheartj/ehz223. No abstract available.

PMID:
31005987
19.

Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study.

Francisci D, Pirro M, Schiaroli E, Mannarino MR, Cipriani S, Bianconi V, Alunno A, Bagaglia F, Bistoni O, Falcinelli E, Bury L, Gerli R, Mannarino E, De Caterina R, Baldelli F.

Open Forum Infect Dis. 2019 Mar 7;6(4):ofz112. doi: 10.1093/ofid/ofz112. eCollection 2019 Apr.

20.

Risk of stroke after transcatheter aortic valve implant: the role of the new oral anticoagulants.

Muscente F, De Caterina R.

Eur Heart J Suppl. 2019 Mar;21(Suppl B):B50-B51. doi: 10.1093/eurheartj/suz016. Epub 2019 Mar 29. No abstract available.

21.

Oxidative stress and vascular stiffness in hypertension: A renewed interest for antioxidant therapies?

Massaro M, Scoditti E, Carluccio MA, De Caterina R.

Vascul Pharmacol. 2019 May;116:45-50. doi: 10.1016/j.vph.2019.03.004. Epub 2019 Apr 1. Review.

PMID:
30946986
22.

Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).

Rohla M, Weiss TW, Pecen L, Patti G, Siller-Matula JM, Schnabel RB, Schilling R, Kotecha D, Lucerna M, Huber K, De Caterina R, Kirchhof P.

BMJ Open. 2019 Mar 30;9(3):e022478. doi: 10.1136/bmjopen-2018-022478.

23.

Deficiency of NDUFC2: Cause or bystander in acute coronary syndromes?

Madonna R, Vitulli P, Pierdomenico S, De Caterina R.

Int J Cardiol. 2019 Jul 1;286:134-135. doi: 10.1016/j.ijcard.2019.03.024. Epub 2019 Mar 14. No abstract available.

PMID:
30905519
24.

The epicardial adipose tissue and the coronary arteries: dangerous liaisons.

Madonna R, Massaro M, Scoditti E, Pescetelli I, De Caterina R.

Cardiovasc Res. 2019 May 1;115(6):1013-1025. doi: 10.1093/cvr/cvz062.

PMID:
30903194
25.

Predictors of strut coverage of drug eluting stent implantation in diabetic patients- Is only on-clopidogrel platelet reactivity enough? Reply.

Briguori C, Quintavalle C, Donahue M, D'Alessio F, D'Amore C, Signoriello G, De Caterina R, Condorelli G.

Int J Cardiol. 2019 May 15;283:95. doi: 10.1016/j.ijcard.2019.02.052. No abstract available.

PMID:
30890251
26.

Antioxidant and Anti-Inflammatory Properties of Nigella sativa Oil in Human Pre-Adipocytes.

Bordoni L, Fedeli D, Nasuti C, Maggi F, Papa F, Wabitsch M, De Caterina R, Gabbianelli R.

Antioxidants (Basel). 2019 Feb 25;8(2). pii: E51. doi: 10.3390/antiox8020051.

27.

The co-predictive value of a cardiovascular score for CV outcomes in diabetic patients with no atrial fibrillation.

Patti G, Sticchi A, Pasceri V, Ricci F, Renda G, Hamrefors V, Melander O, Sutton R, Engström G, De Caterina R, Fedorowski A.

Diabetes Metab Res Rev. 2019 Jul;35(5):e3145. doi: 10.1002/dmrr.3145. Epub 2019 Mar 18.

PMID:
30790434
28.

Thrombotic and hemorrhagic burden in women: Gender-related issues in the response to antithrombotic therapies.

Renda G, Patti G, Lang IM, Siller-Matula JM, Hylek EM, Ambrosio G, Haas S, De Caterina R; Working Group on Thrombosis of the Italian Society of Cardiology.

Int J Cardiol. 2019 Jul 1;286:198-207. doi: 10.1016/j.ijcard.2019.02.004. Epub 2019 Feb 8. Review.

PMID:
30777407
29.

Three-Dimensional Echographic Evaluation of Carotid Artery Disease.

Calogero E, Fabiani I, Pugliese NR, Santini V, Ghiadoni L, Di Stefano R, Galetta F, Sartucci F, Penno G, Berchiolli R, Ferrari M, Cioni D, Napoli V, De Caterina R, Di Bello V, Caramella D.

J Cardiovasc Echogr. 2018 Oct-Dec;28(4):218-227. doi: 10.4103/jcecho.jcecho_57_18. Review.

30.

Is there an 'atherosclerotic continuum' from angina with unobstructed coronary arteries to MINOCA? Reply.

Radico F, Zimarino M, De Caterina R.

Eur Heart J. 2019 Jun 21;40(24):1988. doi: 10.1093/eurheartj/ehy918. No abstract available.

PMID:
30689819
31.

Early Subclinical Atherosclerosis in Gestational Diabetes: The Predictive Role of Routine Biomarkers and Nutrigenetic Variants.

Franzago M, Fraticelli F, Di Nicola M, Bianco F, Marchetti D, Celentano C, Liberati M, De Caterina R, Stuppia L, Vitacolonna E.

J Diabetes Res. 2018 Dec 24;2018:9242579. doi: 10.1155/2018/9242579. eCollection 2018.

32.

Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation.

Patti G, Pecen L, Lucerna M, Huber K, Rohla M, Renda G, Siller-Matula J, Ricci F, Kirchhof P, De Caterina R.

Am J Med. 2019 Jun;132(6):749-757.e5. doi: 10.1016/j.amjmed.2018.12.036. Epub 2019 Jan 19.

33.

ESC Working Group on Cellular Biology of the Heart: position paper for Cardiovascular Research: tissue engineering strategies combined with cell therapies for cardiac repair in ischaemic heart disease and heart failure.

Madonna R, Van Laake LW, Botker HE, Davidson SM, De Caterina R, Engel FB, Eschenhagen T, Fernandez-Aviles F, Hausenloy DJ, Hulot JS, Lecour S, Leor J, Menasché P, Pesce M, Perrino C, Prunier F, Van Linthout S, Ytrehus K, Zimmermann WH, Ferdinandy P, Sluijter JPG.

Cardiovasc Res. 2019 Mar 1;115(3):488-500. doi: 10.1093/cvr/cvz010.

PMID:
30657875
34.

Impact of Sex Differences and Diabetes on Coronary Atherosclerosis and Ischemic Heart Disease.

Madonna R, Balistreri CR, De Rosa S, Muscoli S, Selvaggio S, Selvaggio G, Ferdinandy P, De Caterina R.

J Clin Med. 2019 Jan 16;8(1). pii: E98. doi: 10.3390/jcm8010098. Review.

35.

Spontaneous conversion in patients with non-valvular atrial fibrillation planned for electrical cardioversion: A subanalysis of the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion Of Atrial Fibrillation (ENSURE-AF) trial.

Cohen AA, Heidbuchel H, Le Heuzey JY, De Caterina R, Merino JL, Jin J, Melino M, Winters SM, Goette A, Lip GYH.

Am Heart J. 2019 Mar;209:131-135. doi: 10.1016/j.ahj.2018.10.008. Epub 2018 Nov 22. No abstract available.

PMID:
30635112
36.

The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations.

De Caterina R, Ageno W, Agnelli G, Chan NC, Diener HC, Hylek E, Raskob GE, Siegal DM, Verheugt FWA, Lip GYH, Weitz JI.

Thromb Haemost. 2019 Jan;119(1):14-38. doi: 10.1055/s-0038-1675816. Epub 2018 Dec 31. Review.

PMID:
30597497
37.

Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.

De Caterina R, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sá E, Weiss TW, Waltenberger J, Steffel J, de Groot JR, Levy P, Bakhai A, Zierhut W, Laeis P, Reimitz PE, Kirchhof P; ETNA-AF-Europe investigators.

J Cardiovasc Med (Hagerstown). 2019 Feb;20(2):97-104. doi: 10.2459/JCM.0000000000000737.

PMID:
30540648
38.

Mid-term outcomes after percutaneous interventions in coronary bifurcations.

Zimarino M, Briguori C, Amat-Santos IJ, Radico F, Barbato E, Chieffo A, Cirillo P, Costa RA, Erglis A, Gamra H, Gil RJ, Kanic V, Kedev SA, Maddestra N, Nakamura S, Pellicano M, Petrov I, Strozzi M, Tesorio T, Vukcevic V, De Caterina R, Stankovic G; EuroBifurcation Club.

Int J Cardiol. 2019 May 15;283:78-83. doi: 10.1016/j.ijcard.2018.11.139. Epub 2018 Dec 2.

PMID:
30528620
39.

[Usefulness, timing and modality of ECG stress testing after myocardial revascularization].

Massacesi C, Zimarino M, Angeramo F, Piedimonte G, Emdin M, Piepoli MF, De Caterina R.

G Ital Cardiol (Rome). 2018 Dec;19(12):692-704. doi: 10.1714/3027.30253. Review. Italian.

PMID:
30520883
40.

Predictors of strut coverage of drug eluting stent implantation in diabetic patients.

Briguori C, Quintavalle C, Donahue M, D'Alessio F, D'Amore C, Signoriello G, Del Vecchio L, De Caterina R, Condorelli G.

Int J Cardiol. 2019 Feb 1;276:61-65. doi: 10.1016/j.ijcard.2018.11.025. Epub 2018 Nov 9.

PMID:
30473337
41.

The first 3500 years of aspirin history from its roots - A concise summary.

Montinari MR, Minelli S, De Caterina R.

Vascul Pharmacol. 2019 Feb;113:1-8. doi: 10.1016/j.vph.2018.10.008. Epub 2018 Nov 2. Review.

PMID:
30391545
42.

Non-Vitamin K Antagonist Oral Anticoagulants for Mechanical Heart Valves.

Aimo A, Giugliano RP, De Caterina R.

Circulation. 2018 Sep 25;138(13):1356-1365. doi: 10.1161/CIRCULATIONAHA.118.035612. Review.

PMID:
30354416
43.

[Fourth universal definition of myocardial infarction (2018)].

Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, Mickley H, Crea F, Van de Werf F, Bucciarelli-Ducci C, Katus HA, Pinto FJ, Antman EM, Hamm CW, De Caterina R, Januzzi JL Jr, Apple FS, Alonso Garcia MA, Underwood SR, Canty JM Jr, Lyon AR, Devereaux PJ, Zamorano JL, Lindahl B, Weintraub WS, Newby LK, Virmani R, Vranckx P, Cutlip D, Gibbons RJ, Smith SC, Atar D, Luepker RV, Robertson RM, Bonow RO, Steg PG, O'Gara PT, Fox KAA.

Kardiol Pol. 2018;76(10):1383-1415. doi: 10.5603/KP.2018.0203. Polish. No abstract available.

44.

Direct Oral Anticoagulants Halve Thromboembolic Events After Cardioversion of AF Compared With Warfarin.

Kotecha D, Pollack CV Jr, De Caterina R, Renda G, Kirchhof P.

J Am Coll Cardiol. 2018 Oct 16;72(16):1984-1986. doi: 10.1016/j.jacc.2018.07.083. No abstract available.

45.

Low-Thrombogenicity Mechanical Heart Valves: Which Antithrombotic Strategy?

Aimo A, Emdin M, De Caterina R.

J Am Coll Cardiol. 2018 Oct 9;72(15):1878-1879. doi: 10.1016/j.jacc.2018.07.065. No abstract available.

46.

Marine n-3 Fatty Acids and Vascular Disease: Solid Evidence in a Sea of Uncertainties.

De Caterina R, Madonna R.

J Am Coll Cardiol. 2018 Oct 2;72(14):1585-1588. doi: 10.1016/j.jacc.2018.07.044. No abstract available.

47.

Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs.

Patti G, Cavallari I, Andreotti F, Calabrò P, Cirillo P, Denas G, Galli M, Golia E, Maddaloni E, Marcucci R, Parato VM, Pengo V, Prisco D, Ricottini E, Renda G, Santilli F, Simeone P, De Caterina R; Working Group on Thrombosis of the Italian Society of Cardiology.

Nat Rev Cardiol. 2019 Feb;16(2):113-130. doi: 10.1038/s41569-018-0080-2. Review.

PMID:
30250166
48.

Prognostic Role of Cardiac Magnetic Resonance in Arrhythmogenic Right Ventricular Cardiomyopathy.

Aquaro GD, Pingitore A, Di Bella G, Piaggi P, Gaeta R, Grigoratos C, Altinier A, Pantano A, Strata E, De Caterina R, Sinagra G, Emdin M.

Am J Cardiol. 2018 Nov 15;122(10):1745-1753. doi: 10.1016/j.amjcard.2018.08.007. Epub 2018 Aug 21.

PMID:
30220419
49.

Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries.

Patti G, Pecen L, Lucerna M, Huber K, Rohla M, Renda G, Siller-Matula J, Schnabel RB, Cemin R, Kirchhof P, De Caterina R.

Int J Cardiol. 2018 Nov 1;270:160-166. doi: 10.1016/j.ijcard.2018.06.098. Epub 2018 Jun 28.

PMID:
30220376
50.

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation.

Christersson C, Wallentin L, Andersson U, Alexander JH, Alings M, De Caterina R, Gersh BJ, Granger CB, Halvorsen S, Hanna M, Huber K, Hylek EM, Lopes RD, Oh BH, Siegbahn A.

Heart. 2019 Feb;105(3):235-242. doi: 10.1136/heartjnl-2018-313351. Epub 2018 Sep 12.

Supplemental Content

Loading ...
Support Center